FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to pharmaceutical products in oncology. Disclosed are: a pharmaceutical combination for treating cancer, comprising a MET tyrosine kinase inhibitor, which is INC280 of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a tyrosine kinase EGFR inhibitor which is (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisolinicotinamide or a pharmaceutically acceptable salt thereof (and versions of treating lung cancer), and a corresponding method of treating cancer.
INC280 compound of formula (I)
EFFECT: combination (and method of treatment with its use) is effective against gefitinib-resistant cancer.
29 cl, 12 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| PHARMACOLOGICALLY ACTIVE COMPOUNDS AS INHIBITORS OF THE TAM FAMILY RECEPTOR TYROSINE KINASE | 2016 |
|
RU2750727C2 |
| NEW COMBINATION OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1N-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1N-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND TYROSINE KINASE INHIBITOR EGFR | 2016 |
|
RU2695362C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| DI(ARYLAMINO)ARYL COMPOUNDS | 2008 |
|
RU2463299C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
